Therapy Insight: pyoderma gangrenosum - old disease, new management

被引:12
作者
Campbell, S
Cripps, S
Jewell, DP
机构
[1] John Radcliffe Hosp, Dept Gastroenterol, Oxford OX3 9DU, England
[2] John Radcliffe Hosp, Dept Pharm, Oxford OX3 9DU, England
来源
NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY | 2005年 / 2卷 / 12期
关键词
Crohn's disease; neutrophilic dermatoses; pyoderma gangrenosum; therapy; ulcerative colitis;
D O I
10.1038/ncpgasthep0339
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Well-designed studies that help guide physicians to apply the optimal therapeutic strategy for the management of pyoderma gangrenosum are lacking in the literature. A multidisciplinary approach is paramount for the effective management of this condition, with close involvement of a wound-care specialist and a microbiologist. Treatment should be stepwise in nature. Local wound care, avoidance of trauma and the application of local steriod or tacrolimus ointment are the first-line treatments. Steriod therapy is the most widely published effective therapy for achieving resolution of pyoderma gangrenosum, although there is growing evidence for the efficacy of infliximab in refractory cases. Other therapies such as dapsone and clofazamine should be left as third-line agents for refractory pyoderma gangrenosum, while novel treatments such as granulocyte apheresis should only be used under trial conditions, to gain an objective evaluation of their efficacy. This article reviews the published treatment strategies in current use, and aims to guide the effective management of pyoderma gangrenosum.
引用
收藏
页码:587 / 594
页数:8
相关论文
共 51 条
[1]   Aberrant neutrophil trafficking and metabolic oscillations in severe pyoderma gangrenosum [J].
Adachi, Y ;
Kindzelskii, AL ;
Cookingham, G ;
Shaya, S ;
Moore, EC ;
Todd, RF ;
Petty, HR .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1998, 111 (02) :259-268
[2]   Leg ulcers in patients with myeloproliferative disorders:: Disease- or treatment-related? [J].
Bader, U ;
Banyai, M ;
Böni, R ;
Burg, G ;
Hafner, J .
DERMATOLOGY, 2000, 200 (01) :45-48
[3]   Pyoderma gangrenosum as an early revelator of acute leukemia [J].
Beele, H ;
Verhaeghe, E ;
Stockman, A ;
Janssens, A ;
Noens, L ;
Geerts, ML ;
Huys, I ;
Naeyaert, JM .
DERMATOLOGY, 2000, 200 (02) :176-178
[4]  
Bernstein CN, 2001, AM J GASTROENTEROL, V96, P1116
[5]   In vivo modulation of leukocyte trafficking receptor following therapeutic purging of myeloid cells: implications for treatment of HIV infection and other immune disorders [J].
Biswas, P ;
Mantelli, B ;
Hasson, H ;
Vecchi, A ;
Saniabadi, A ;
Lazzarin, A ;
Beretta, A .
CLINICAL IMMUNOLOGY, 2003, 109 (03) :355-358
[6]   IDIOPATHIC PYODERMA GANGRENOSUM AND IMPAIRED LYMPHOCYTE FUNCTION - FAILURE OF AZATHIOPRINE AND CORTICOSTEROID-THERAPY [J].
BREATHNACH, SM ;
WELLS, GC ;
VALDIMARSSON, H .
BRITISH JOURNAL OF DERMATOLOGY, 1981, 104 (05) :567-573
[7]  
Brooklyn TN, 2005, GUT, V54, pA23
[8]   Pyoderma (echthyma) gangrenosum - Clinical and experimental observations in five cases occurring in adults [J].
Brunsting, LA ;
Goeckerman, WH ;
O'Leary, PA .
ARCHIVES OF DERMATOLOGY AND SYPHILOLOGY, 1930, 22 (04) :655-680
[9]   Pyoderma gangrenosum in myelodysplasia responding to granulocyte macrophage-colony stimulating factor (GM-CSF) [J].
Bulvik, S ;
Jacobs, P .
BRITISH JOURNAL OF DERMATOLOGY, 1997, 136 (04) :637-638
[10]   Pyoderma gangrenosum [J].
Callen, JP .
LANCET, 1998, 351 (9102) :581-585